Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002266 · ClinicalTrials.gov registry record · NA

An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients

A NA study of HIV Infections, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002266: Completed NA study of HIV Infections, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

NCT00002266 is a NA study of HIV Infections that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002266, a NA study of HIV Infections, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

To compare AS-101 dosing schedules (once a week; 3 times a week; 5 times a week; or 5 times per week on alternate weeks) on the effect on clinical immunology and virus burden in AIDS or AIDS related complex (ARC) patients.

Conditions Studied

HIV Infections

Interventions

  • DRUG AS-101

Study Locations (1)

Arizona

  • Univ of Arizona / Health Science Ctr - Tucson

Trial Details

FieldValue
Phase NA
Wyeth is now a wholly owned subsidiary of Pfizer

167 total trials

What the finished NCT00002266 record still lists

NCT00002266 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which AS-101 is the first listed.

NCT00002266 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT00002266 about?

NCT00002266 is a clinical study titled "An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients". To compare AS-101 dosing schedules (once a week; 3 times a week; 5 times a week; or 5 times per week on alternate weeks) on the effect on clinical immunology and virus burden in AIDS or AIDS related complex (ARC) patients.

What is the current status of trial NCT00002266?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002266 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002266?

The interventions under investigation include: AS-101 (DRUG).

Who is sponsoring clinical trial NCT00002266?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002266 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002266, the US trial registry maintained by the National Library of Medicine. NCT00002266 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.